154 related articles for article (PubMed ID: 32898008)
1. Serum Exo-EphA2 as a Potential Diagnostic Biomarker for Pancreatic Cancer.
Wei Q; Zhang J; Li Z; Wei L; Ren L
Pancreas; 2020 Oct; 49(9):1213-1219. PubMed ID: 32898008
[TBL] [Abstract][Full Text] [Related]
2. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
3. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
4. EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer.
Wei Q; Wei L; Zhang J; Li Z; Feng H; Ren L
Mol Med Rep; 2020 Oct; 22(4):2941-2947. PubMed ID: 32945400
[TBL] [Abstract][Full Text] [Related]
5. Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer.
Wei Q; Li Z; Feng H; Ren L
Cancer Manag Res; 2021; 13():3675-3683. PubMed ID: 33994808
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
7. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
8. Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19-9 and CEA.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Pol Arch Intern Med; 2018 Sep; 128(9):524-531. PubMed ID: 30057378
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
10. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
[TBL] [Abstract][Full Text] [Related]
11. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
[TBL] [Abstract][Full Text] [Related]
12. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
[TBL] [Abstract][Full Text] [Related]
13. Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer.
Koshikawa N; Minegishi T; Kiyokawa H; Seiki M
Cell Death Dis; 2017 Oct; 8(10):e3134. PubMed ID: 29072678
[TBL] [Abstract][Full Text] [Related]
14. Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study.
Tartaglione S; Pecorella I; Zarrillo SR; Granato T; Viggiani V; Manganaro L; Marchese C; Angeloni A; Anastasi E
Biochem Med (Zagreb); 2019 Jun; 29(2):020707. PubMed ID: 31223261
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
16. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
[TBL] [Abstract][Full Text] [Related]
18. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
19. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
20. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection.
Chang YT; Wu CC; Shyr YM; Chen TC; Hwang TL; Yeh TS; Chang KP; Liu HP; Liu YL; Tsai MH; Chang YS; Yu JS
PLoS One; 2011; 6(5):e20029. PubMed ID: 21625447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
